Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mendus ABCHIX:IMMUS 31 3-Year EBITDA Growth Rate is 44.90% as of Mar. 2026. GuruFocus rates CHIX:IMMUS with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,130 Biotechnology companies, Mendus AB ranks better than 81.5% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 44.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 39.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 26.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mendus AB was 44.90% per year. The lowest was -85.80% per year. And the median was -2.10% per year.
Mendus AB (CHIX:IMMUs) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Mendus AB 3-Year EBITDA Growth Rate Related Terms
CHIX:IMMUS vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Mendus AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mendus AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mendus AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Mendus AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 44.90% mean?
Mendus AB (CHIX:IMMUS) has a 3-Year EBITDA Growth Rate of 44.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mendus AB and its competitors. According to the industry distribution chart, Mendus AB ranks #209 out of 1130 companies in the Biotechnology industry, placing it in the top 18.5%.
Is Mendus AB's 3-Year EBITDA Growth Rate too high?
Mendus AB's current 3-Year EBITDA Growth Rate is 44.90%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Mendus AB's value of 44.90% is 202.4% above this industry median. Based on the distribution chart, Mendus AB ranks #209 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mendus AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Mendus AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mendus AB ranks #209 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Mendus AB in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Mendus AB's value of 44.90% is 202.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mendus AB's current 3-Year EBITDA Growth Rate of 44.90% is 202.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mendus AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mendus AB's current 3-Year EBITDA Growth Rate is 44.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mendus AB stock overvalued right now?
Mendus AB (CHIX:IMMUS) has a current 3-Year EBITDA Growth Rate of 44.90%. The current 3-Year EBITDA Growth Rate is 44.90% and 202.4% above the Biotechnology industry median of 14.85. Mendus AB's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Mendus AB (CHIX:IMMUS), the current 3-Year EBITDA Growth Rate is 44.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
31GF Score
Get the complete analysis for CHIX:IMMUS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:IMMUS has been successfully added to your 
